ETHOXYCARBONYLOXY ETHYL ESTERS OF NON-STEROIDAL ANTI-INFLAMMATORY CARBOXYLIC ACIDS, THEIR PREPARATION AND USE

Abstract: The invention provides esters of the general formula in which R-- is the acyl residue of a non-steroidal anti-inflammatory compound containing a carboxylic acid function. The esters may be prepared by reacting an acid R-COOH, when R is as above, with a 1-haloethyl ethyl carbonate. The esters may be formulated to provide pharmaceutically or veterinarily acceptable formulations.

Description: ETHOXYCARBONYLOXY ETHXL ESTERS OF NON-STROIDAL ANTI-INFLAMMATORY CARBOXYLIC ACIDS, THEIR PREPARATION AND USE The present invention concerns novel etboxy- carbonyloxy ethyl esters of non-steroiaal antiinflammatory substances having a carboxylic acid function, a process for their preparation and pharmaceutidal or veterinary formulations containing them. The novel esters accoraino to the invention are prodrugs of the corresponding non-steroidal antiinflammatory substances. In the context of the present specification the term "prodrug" denotes a derivative 61 a known and proven prior art non-steroidal antiinflammatory substance having a carboxylic acid function, such as for example 2-(acetyl)salicylic acid (Aspirin), or compounds known by their generic names such as, for example, indomethacin, ibupro@en, napro@en and diclofenac, which derivatives when administered cleave in such a manner as to release the proven anti-inflammatory compound in its carboxylic acid form at its target site or sites of activity. The enzymatic and/or chemical hydrolytic cleavage of the compounds of the present invention occurs in such a manner that the proven drug, i.e. the conventional non-steroidal anti-inflammatory substance, is released. The remaining cleaved moiety is non-toxic and is metabolized in such a manner that non-toxic metabolic products are produced such as ethanol, CO2 and acetaldehyde. It is known that the un-ionized form of a drug is absorbed more efficiently than its ionic species.In the case of non-steroidal anti-inflammatory drugs Containing 2 carboxylic acd function such as those known by the generic names indomethacin, naproxen, ibuprof en or diclofenac the -carboxylic acid is significantly ionized at physiological pH.The result is that such non-steroidal anti-inflammatory drugs are poorly absorbed through lipid-water membrane barriers and are irritating to the mucous membrane of the intestinal tract. European Patent Application Publication No. 0039051 discloses novel prodrug forms of known non-steroidal antiinflammatory agents having a free carboxylic acid function, which are acetohydroxamic acid derivatives of the formula EMI3.1 wherein EMI3.2 is the acyl residue of any non-steroidal antiinflammatory substance containing a carboxylic acid function, R1 and R2 stand for a variety of organic radicals and may also form together with the nitrogen atom to which they are attached a heterocyclic ring, and R3 stands for -hydrogen or a variety of organic radicals. However, these prodrugs are of a rather complex nature and are not readily accessible. Thus the process for the preparation of these prodrugs as described in the said European patent application comprises four stages. In the first of these a nonsteroidal anti-inflammatory agent having a free carboxylic acid function is converted into the corresponding acid chloride, e.g. by reaction with thionyl chloride. In a second stage the resulting acid chloride is reacted with hydroxyl amine to form a corresponding hydroxamic acid. The latter is then reacted with an aldehyde and the resulting reaction product is reacted with a secondary amine. (See pages 14 and 15 of the European patent application. In addition to the chemical complexity of the prodrug forms of non-steroidal anti-inflammatory substances according to the said European patent application, it is also difficult to predict which of the large variety of acetohydroxamic acid moieties is of sufficiently low toxicity and yields metabolites of sufficiently low toxicity as to be harmless upon cleavage of the prodrug in the body of a mammal. It is accordingly the object of the present invention to provide novel, improved prodrug forms of known non-steroidal anti-inflammatory substances having a carboxylic function. It is a further object of the present invention to provide non-steroidal antiinflammatory agents of reduced ulcerogenicity. It is known from the literature, e.g. from British Patent Specification No. 1,363,506, to convert a-amino penicillins and penicillin G into the corresponding l'-ethoxycarbonyloxy ethyl esters and it has been found that the absorption of such esters from the intestinal tract is superior to the absorption of a corresponding penicillin in the free acid form. However, the art of anti-bacterial and antibiotic drugs is different from that of non-steroidal anti-inflammatory agents and the knowledge of the said penicillin esters did not induce people versed in the art of anti-inflammatory agents to look for prodrugs in the form of ethoxycarbonyloxy ethyl esters as manifested by the said European Patent Application No. 81103066.7 which was filed about ten years later. In accordance with the present invention it has now surprisingly been found thatl-ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory substances having a free carboxylic function are excellent prodrug forms of these anti-inflammatory substances possessing increased bioavailability and reduced ulcerogenicity when adrninistered orally as compared to the non-steroidal anti-inflammatory drugs with a free carboxylic function from which they are derived. The present invention thus provides a novel group of compounds of the general formula EMI6.1 in which EMI6.2 is the acyl residue of a non-steroidal anti-inflammatory compound containing a carboxylic acid function. The chemical structure of the non-steroidal anti-inflammatory compounds RCOOH,whose acyl residue R-Cis the acyl moiety of the novel esters according to the invention,-is not critical; non-limiting examples are acetyl salicylic acid (Aspirin); indomethacin, naproxen, ibuprofen, sulindac, diflunisal, ketoprofen, mefenamic acid, tolmetin, diclofenac and fluferaI1ic acid. On oral administration the esters according to the invention are readily absorbed from the digestive tract and liberate the anti-inflammatory substance in the free carboxylic form in the blood and in this way a high drug concentration is maintained in the blood over long periods of time. This highly advantageous property of the novel esters according to the invention is believed to be due to the fact that while these esters readily undergo enzymatic hydrolysis in-vivo they have a certain resistence to hydrolysis in an aqueous acidic medium. Thus, for example, the 2-ethoxycarbonyloxy ethyl ester of acetyl salicylic acid (Aspirin) is not readily hydrolysed off in an aqueous acidic medium (simulated gastric juices) in contrast to the acetyl group of this drug which is readily hydrolsed off under the same conditions. Similarly, the 1'-ethoxycarbonyly ethyl ester of salicylic acid is stable in acidic media Likewise the rate of hydrolysis in 0.01 N nC1 solution at 250C of other esters according to the invention was found to be relatively slow (half-life of 32 hours assuming pseudo-first order kinetics). Against this the rate of hydrolysis in-vitro in human plasma was found to be much faster with a half-life of 2.3 hours at 250C. These results show that the esters of the present invention are readily hydrolized when subjected to the influence of hydrolytic enzymes, for instance such as are present in blood serum, while being relatively resistant to hydrolysis in acidic medium such as the gastric juices. In consequence the release of the active non-steroidal anti-inflammatory substance in the free carboxylic acid form from the prodrug form occurs prior to or during absorption processes. The novel prodrugs according to the invention may be prepared in a simple one-step reaction in which a compound of the general formula EMI7.1 wherein EMI7.2 has the same meaning as before, or a salt thereof, is reacted with a l-haloethyl ethyl carbonate of the formula EMI8.1 wherein X represents a halogen atom. Where a free carboxylic acid is used as starting material for the reaction with l-haloethyl ethyl carbonate to produce the novel esters according to the invention the reaction is preferably performed in the presence of a base such as for example a trialkylamine, e.g. triethylamine, a metal bicarbonate such as potassium bicarbonate or sodium bicarbonate, or metal carbonates such as sodium and potassium carbonate. Where a salt is used as starting material the reaction proceeds favourably in the absence of a base. Preferably, compounds of the above formula III in which X is C1 or Br are used and of these the bromo compound is particularly preferred. This is because - the C-Br bond is more labile than the C-C1 bond and that in consequence l-bromoethyl ethyl carbonate is more reactive than the corresponding chloro compound. In consequence the rate of esterification with l-bromoethyl ethyl carbonate is significantly faster than with a different 1-haloethyl -ethyl carbonate, e.g. l-chloroethyl ethyl carbonate,and there is as a rule no need for a large excess of the l-bromoethyl ethyl carbonate nor are high temperatures and the use of catalysts required. The fact thatthe esterification with l-bromoethyl ethyl carbonate proceeds under relatively mild conditions is of particular signigicance having regard to the sensitivity of some of the non-steroidal anti-inflammatory substances in the free carboxylic acid form whose ester prodrugs are produced in accordance with the present invention. 1-Bromoethyl ethyl carbonate is a compound which has only recently been prepared. However, it has now been found that it may be used to produce novel prod rug esters according to the invention in answer to the long-felt want for readily accessible and effective prodrugs of nonsteroidal anti-inflammatory substances. 1-Bromoethyl ethyl carbonate can be produced by brominating diethyl carbonate with elementary bromine or a brominating agent, e.g. 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione, in an aprotic inert solvent and under conditions conducive of free radical formation, the amount of bromine made available in the bromination being not more than the stoichiometric quantity. For free radical initiation it is possible to use light or a free radical initiator such as, for example, azobisisobutyronotrile. The invention is illustrated by the following Examples without being limited thereto. Example 1 is concerned with the preparation of the 1-bromoethyl ethyl carbonate starting material. Example 1 Production of 1-bromoethyl ethyl carbonate A mixture of 195 g diethylcarbonate and 500 ml of 1,1,2-trichloro- trifluoroethane was irradiated externally by a 1.5 km iodine-quartz lamp. The mixture soon ref fluxed by the heat evolved fran the lart:.The temperature in the flask was 60 C. 79.0 g of 1,3-dibromo-5,5-dimethylimidazoline-2,4-dione was added in small portions during 6 hours. The mixture was irradiated and refluxed for another 20 minutes and cooled. Solids were removed by filtration. The solution was frac tionally distilled first at atmospheric pressure and then under vacuum. l-Bromoethyl ethyl carbonate was distilled at 910 at 20 mm Hg pressure. The fraction weighed 60 g and was shown to be 98% pure, by GC, The following are physical data of l-bromoethyl ethyl carbonate: Boiling point at 60 mm Hg - 1100 Bromine content 40.6% (theoretical 40.618) Density (D 24) 1.4244 (n20 Refraction index & 1.4395 NMR Spectrum : 1.4 ppm 3H triplet J = 7 Hz 2.0 ppm 3H doublet J = 6 Hz 4.25 ppm 2H guartet J = 7 Hz 6.6 ppm 1H quartet J = 6 Hz Example 2 The preparation of 1'-ethoxy carbonyloxy ethyl ester of 2-tacetyloxy)benzoic acid (Aspirin). Anhydrous potassium carbonate (0.3 equivalent) was added to a solution of 2-(acetyloxy)benzoic acid (Aspirin) (0.12mole) in acetone. To the mixture, 1.2 mole of l-bromsethyl ethyl carbonate was added and the mixture was heated for 3 hours at -reflux. The cooled mixture was poured into water and stirred for 1 hour, at room temperature. The organic phase was separated, the aqueous phase extracted with methylenechloride and the combined organic phases washed with water and dried over MgSO4. A pure oily product was obtained in 80e yield after evaporation of the methylene chloride. IR (neat): 1760 and 1740 cm (s) EMI11.1 NMR, 6(CDCl3): 8.15 - 7.4 (4H, multiplet) Aromatic 7.15 (lH, AB quartet) CH3 - CH - 0 4.3 (2H, AB quartet) CH3 - CH2 - 0 2.35 (3H, s) CH3CO 1.6 (3E, d) CH3 - CHO 1.35 (3H, t) CH3 - CH2 - 0 Anal. calcd. for C14H16O7 (m.w 296) C 56.76 H 5.41 found C 56.63 H 5.31 Example 3 The preparation of l'-ethoxy carbonyloxy ethyl ester of salicylic acid. Equimolar quantities (0.072 mole) of salicylic acid (10 g), NaHCO3 (7.1 g) and l-chloroethyl ethyl carbonate were added to 70ml DMSO. The mixture was stirred at room. temperature, until no starting material could be detected (TLC). The mixture was poured into water, stirred for 1 hour and then extracted with CH2Cl2. The organic layer was separated, washed with NaHCO3 solution, then with water and dried over MgSO4. The oily residue obtained after evaporation of CH2Cl2 contained traces of unreacted l-chloroethyl ethyl carbonate, DMSO and the product. Column chromatography on silica with CH2Cl2 afforded 8 g (41%) pure colourless oily product. Better yields were obtained by reacting directly sodium salicylate with l-bromoethyl ethyl carbonate. IR (neat) 1765 and 1745 cm l (s) NMR, 6(CDCl3) 7.33 (6H, m, Ar + OH + CH3CHO) 4.16 (2H, q, OCH2CH3) 2.26 (3H, d, CH3CHO) 1.26 (3H, t, CH3CH2O) By following the procedure of the foregoing Samples several more novel esters according to the invention of non-steroidal anti-inflammatory substances were prepared. In the following Examples 4 to 13 only the generic and chemical designations, the structural formulae and the physical properties of the products are given. In the generic and designation and structural formulae the abbreviation ECOE'is used for the ethoxycarbonyl ethyl moiety Example 4 1-(p-Chloro@enzoy])-5-methoxy-2-methylindole- 3-acctic acid 1'-ethoxycarbonyloxy ethyl ester. EMI13.1 Indomethacin - ECOE ester Solid, melting point 86.7 C (isopropanol hexane) -1 IR cm 1760 1740 NMR #, in CDCl3 7.6 6.4 (8H, m, Ar + CH3-CHO) 4.0 (2H, q, CH3-CH2-O) 3.7 (3H, s, CH3O) 3.6 (2H, s, CH2CO) 2.25 (3H, s, CH3CO) 1.5 (3H, d, CH3-CH) 1.2 (3H, t, CH3CH2) Example 5 (+)-6-Methoxy-&alpha;-methyl-2-naphthaleneacetic acid 1'-ethoxycarbonyloxy ethyl ester. EMI13.2 Naproxen - ECOE ester Oi3 at room temperature IR cm-1 1760 1740 NMR #, in CDCl3 300 M Hz: 7.67-7.12 (6H, Ar) 6.78 (1H, 2q, CH3CHO) 4.18 (2H, q, CH2CH3) 3.85,3.97 (1H, 2q, CH3CHCO) 3.87 (3H, s, CH3O) 1.57 (3H, d, CH3CH) 1.48,1.38 (3H, d, CH3CH) 1.27,1.21 (3H, t, CH3CH2O) Example 6 a-Methyl-4-(2-methylpropyl)benzene - acetic acid 1'-ethoxycarbonyloxy ethyl ester. EMI14.1 Ibuprofen - ECOE ester oil at room temperature IR cm-1 1760 1740 NMR 6, in CDC13 300 M Hz: 7.18-7.06 (4H, q+d, Ar) 6.75 (1H, 2q, CH3CH-O) 4.19,4.09 (2H, 2q, CH3CH2O) 3.69 (1H, 2q, CH3CH) 2.43 (2H, 2d, CH2-CH#) 1.85 (1H, Septet, CH < ) 1.47,1.44 (6H, 2d+d, CHCH3; OCHCH3) 1.30, 1.25 (2H, 2t, CH3CH2) EMI14.2 Example 7 2-[(2,6-Dichlorophenyl)amino]benzene-acetic acid 1'-ethoxycarbonyloxy ethyl ester EMI15.1 Dicloienic - ECOE ester Solid, melting point 570C (MeOH) IR cm 1765 1750 NMR #, in CDCl3 7.28 (8H, Ar + CH3CHO, NH) 4.2 (2H, g, CH3CH20) 3.8 (2H, s, OCH2CH3) 1.5 (3H, d, CH3CHO) 1.3 (3H, t, CH3CH20) Example 8 m-Benzoylbydratropic acid 1'-ethoxycarbonyloxy ethyl este@. EMI16.1 Ketoprofen - ECOE ester Oil at room temperature IR cm-1 1765 1735 NMR #, in CDCl3 7.52 (9H, m, Ar) 6.70 (2H, q, CH3CHO-) 4.09 (1H, 2q, CH3CH2O) 3.76 (1H, 2q, CH3CHCO) 1.53 (3H, d, CH3CHO) 1.40 (3H, d, Me) 1.33 (3H, t, Me) Example 9 2- 1 (2, 3-Dimethylphenyl) amino]-benzoi c acid 1'-ethoxycarbonyloxy ethyl ester. EMI16.2 Mefenamic kcid - ECOE ester oil at room temperature 3320 1755 1745 NMR #, in CDCl3 9.13 (1H, br.s, NH) 7.96 (1H, d, ortho H to coAr) 7.1 (6H, m, Ar +) 6.66 (1H, q, CH3CHO) 4.23 (2H, q, CHECH2O) 2.29 (3H, s, Me) 2.13 (3H, s, Me) 1.69 (3H, d, CH3CH) 1.33 (3H, t, CH3CH2O) Example 10 (Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl] methylene]-1H-indene-3-acetic acid 1'-ethoxycarbonyloxy ethyl ester. EMI17.1 Sulindac - ECOE ester Oil at room temperature IR cm-1 1760 1745 NMR #, in CDC13 7.6 (3H, s, Ar) H 7.25-6.25 (6H, m, Ar = C=C+CH3CHO) 4.15 (2H, q, CH3CH2O) 3.55 (2H, s, CH2CO) 2.75 (3H, s, Me) 2.20 (3H, s, Me) 1.50 (3H, d, CH3CH2) 1.25 (3H, t, 'CH3CH2) Example 11 2-[[3-(Trifluoromethyl)phenyl]-amino]benzoic acid 1'-ethoxycarbonyloxy ethyl ester. EMI18.1 Flufenamic Acid - ECOE ester Oil at room temperature IR cm-1 3320 1755 1745 NMR #, in CDCl3 9.42 (1H, br.s, NH) 7.93 (1H, d, H ortho to CO) 7.03 (8H, m, Ar + CH3CHO) 4.20 (2H, q, CH3CH2O) 1.66 (3H, d, CH3CHO) 1.26 (3H, t, CH3CH2O) Example 12 1-Methyl-5-(&alpha;-methylbenzoyl)-1H-pyrrole-2- ace tic acid 1'-ethoxycarbonyloxy ethyl ester. EMI18.2 Tolmetin - ECOE ester Oil at room temperature IR cm-1 1765 1740 NMR #, in CDCl3 7.49 (4H, ABq, Ar) 6.82 (1H, q, CH3CHO) 6.42 (2H, ABq, Pyrrole H) 4.23 (2H, q, CH3CH2O) 3.93 (3H, s, Me) 3.60 (2H, s, CH2CO) 2.43 (3H, s, ArMe) 1.59 (3H, d, CH3CHO) 1.33 (3H, t, CH3CH2O) The proton, IR, UV and mass spectra and the elemental analyses of all the above esters were in accord with the molecular structure. In each case where optically active non-steroidal anti-inflammatory carboxylic acids were used the NMR spectrum (300 MHz) of the corresponding ethoxy carbonyloxy ethyl ester showed existence of a diasteroisomeric mixture. The rates of hydrolysis of 2-(acetyloxy)benzoic acid (Aspirin) ethoxy carbonyloxy ethyl ester to salicylethoxy carbonyloxy ethyl ester in the aqueous acidic medium (simulated gastro-intestinal juices) were determined by dissolving the ester to a pre-determined concentration in the acidic medium containing THF: aqueous conc. HC1 = 1:1 and the rate of hydrolysis at 37 C was measured by the HPLC method. The results are given in the following table: wime (Min.) Ester (%) 0 100 30 96 60 92 90 90 120 90 150 84 180 82 210 76 The rate of hydrolysis of salicylic acid 2-ethoxycarbonyloxy ethyl ester under the sane experi- mental conditions vas determined in a similar way and this ester was found to be stable. These results show that the 2-ethoxy carbonyloxy ethyl esters of non-steroida anti-inflammatory substances according to the invention are relatively stable against hydrolysis in acidic media. Thus, they are generally absorbed from the gastro-intestinal tract to the blood system in the ester form. From pharmacokinetic data it was further found that the novel esters according to the invention exhibit characteristics of a slow release profile. PHARMACO@OG@CAL T@@TS The anti-inflammatory and analgesic activities of the produrgs of formula (A), as well as their reduced ulceroge@@city and improved bioavailability in comparison with parent non-steroidal anti-inflammatory drups are evi@ent from the results of the tests obtained with representative compounds of the invention. Details of these tests and results are given thereafter. 1. Anti-Inflammatory Activity Test Procedures: (a) Carrageenin-oedema test I. Prior to administration bf test materials and reference compounds, the volume of the right hind paw to the level of the lateral malleolus in all test animals (pre-injection paw volume) was measured with an Hg-displacement volumeter (Hugo Basile, Italy). II. Test materials and reference compounds, suspended in 0.5% CC at-concentrations appropriate to selected dose levels were administered at a constant volume-dosage of 10 ml/kg by oral gavage with a flexible catheter (choke 8) passed down the oesophagus into the lumen of the stomach. Ill. One hour after administration, 0.1 ml of 19 carrageenin suspended in 0.9E sterile saline solution was injected subcutaneously into the sole of the right hind paw. Iv. Vo3une of the injected foot (i.e. oedema intensity) was determined at 1 and 3 hours after carrageenin injection as detailed above in paragraph 1. Evaluation of data Carrageeenin-oedema test The intensity of oedema, expressed as percent increase in the injected foot volume was calculated for each treatment and the control group, by the following equation: (Mean post-injection volume - mean pre-injection volume) x 100/mean pre-injection volume. Anti-inflammatory activity was expressed as percent-inhibition of oedema, which in turn was calculated for each treatment group by the following equation: (Mean percsvnt-increase paw volume of controls mean percent increase paw volume of treated) x 100/mean percent increase paw volume of controls. Table 1 Comparative prophylactic anti-inflammatory activity of test materials, assessed by inhibition of oedema in the Carrageenin-induced rat-paw oedema test EMI23.1 <tb> <SEP> % <SEP> inhibition <tb> Treatment* <SEP> Dosage <SEP> No. <SEP> of <SEP> of <SEP> aedema** <SEP> % <SEP> activity <tb> <SEP> mg/kg <SEP> p.o. <SEP> animals <SEP> vs. <SEP> parent <tb> <SEP> 3 <SEP> hrs*** <SEP> compound <tb> Indomethacin <SEP> 5.0 <SEP> 6 <SEP> 65.1 <tb> Indomethacin-ECOE <SEP> ester <SEP> 6.6 <SEP> 6 <SEP> 65.1 <SEP> 100 <tb> Diclofenac <SEP> 4.0 <SEP> 6 <SEP> 39.3 <SEP> 100 Diclofenac-ECOE <SEP> ester <SEP> 5.6 <SEP> 6 <SEP> 34.6 <SEP> 88 <tb> Acetylsalicylic <SEP> acid <SEP> 100.0 <SEP> 6 <SEP> 31.4 <tb> Acetylsalicylic <SEP> acid EOOE <SEP> ester <SEP> 164.0 <SEP> 6 <SEP> 20.2 <SEP> 64.24 <tb> <SEP> Ibuprofen <SEP> 25.0 <SEP> 6 <SEP> 44.7 <SEP> 100¯ <tb> <SEP> Ibuprofen-ECOE <SEP> ester <SEP> 39.0 <SEP> 6 <SEP> 48.9 <SEP> 107.59 <tb> Naproxen <SEP> 20.0 <SEP> 6 <SEP> 20.2 <SEP> 100¯ <tb> Naproxen-ECOE <SEP> ester <SEP> 30.0 <SEP> 6 <SEP> 28.0 <SEP> 138.9 <tb> * All test materials were administered 1 hour before carrageenin. ** Mean t incr. paw vol. of controls - Mean % incr. paw vol. of treated x 100 Mean % incr. paw vol. of controls ***After sub-plantar injection of 1% carrageenin. (b) -Adjuvant arthritis (chronic inflammation) Adjuvant arthritis test I. Arthritis was induced by subplantar injection into the right hind paw of 0.1 ml of Killed Mycobacterium butyricum, suspended at a concentra tion of 5 mg/ml in liquid paraffin. On Day 21 after subplantar injection, only those animals which clearly developed signs of arthritis were selected and divided by random order into treatment groups. Test materials and reference compounds, suspended in 0.5t C at concentrations appropriate to selected dose levels, and CC only for adjuvant control animals, were administered once daily for 10 consecutive days (i.e. starting on Day 21 after subplantar injection of adjuvant until Day 30). Administration was by oral gavage with a flexible catheter introduced via the oesophagus into the lumen of the stomach. Volume in all cases was 10 ml/kg. III. Swellings of the injected hind paws were measured on Day 31 with a micrometer, across a sagittal section of the matatarsus -just below the tarsus. Evaluation of data The comparative therapeutic anti-inflammatory activity of the test materials and reference compounds was expressed as-percent inhibition of swelling in injected paws after 10 days of treatment (i.e. 31 days after adjuvant injected) in comparison to the non-treated adjuvant-controls. Percent inhibition for each treatment group was calculated by the following equation: (Mean paw swelling of control - mean paw swelling of treated) x 100/mean paw swelling of control. Results: Table 2 Comparative therapentic anti-inflammatory activity of test materials, assessed by inhibition of swclling in the adjuvant-injected rat-naw oedema test. EMI25.1 <tb> <SEP> @ <SEP> inhibition <SEP> of <tb> <SEP> Dosage <SEP> No. <SEP> of <SEP> M@an <SEP> paw <SEP> swelling <SEP> compered <tb> <SEP> Treatment* <SEP> mg/kg <SEP> p.o. <SEP> animals <SEP> swelling@@ <SEP> to <SEP> controis <tb> Adj@@ant <SEP> Control <SEP> (0.5% <SEP> CMC)*** <SEP> - <SEP> 18 <SEP> 15.3 <SEP> Indomethacin <SEP> 2.0 <SEP> 5 <SEP> 10.1 <SEP> 34.0 <tb> Indomethacin-ECOE <SEP> ester <SEP> 2.6 <SEP> 5 <SEP> 9.9 <SEP> 35.3 <tb> Diclofenac <SEP> 2.0 <SEP> 5 <SEP> 10.0 <SEP> 34.6 <tb> Diclofenac-ECOE <SEP> ester <SEP> 2.8 <SEP> 5 <SEP> 10.9 <SEP> 28.8 <tb> Acetylsalicylic <SEP> acid <SEP> 200.0 <SEP> 5 <SEP> 11.8 <SEP> 22.9 <tb> Acetylsalicylic <SEP> acid-ECOE <tb> ester <SEP> 300.0 <SEP> 5 <SEP> 12.4 <SEP> 19.0 <tb> Ibuprofen <SEP> 60.0 <SEP> 5 <SEP> 10.3 <SEP> 32.8 <tb> Ibuprofen-ECOE <SEP> ester <SEP> 94.0 <SEP> 5 <SEP> 10.4 <SEP> 32.0 <tb> Naproxen <SEP> 10.0 <SEP> 5 <SEP> 10.1 <SEP> 34.0 <tb> Naproxen-ECOE <SEP> ester <SEP> 15.1 <SEP> 5 <SEP> 10.9 <SEP> 28.8 <tb> * Administered by daily oral gavae during 10 consecutive days at a volume dosage of 10 ml/kg. ** measured after termination of 10 day treatment (Day 31), expressed as mm units read off micrometer. *** Carboxymethylcellulose in 2 x distilled H2O. 2. knalsesic Action Test Animals t5ale rats, weighing 95-140 g, 10 rats per experimental group. The major reason for selecting rats of this weight range is the ease in handling smaller sized animals in this particular test. Animals are fed and provided drinking water ad libitum until time of testing. Procedure A - Inflammation is induced by injecting subcutaneously 0.1 ml of a 20t suspension of brewers' yeast in saline into the plantar surface of the right hind paw of the rat. (Note: Brewers' yeast, locally obtainable from "Abir" breweries, may be kept under refrigeration for a period of at least 6 months). B - One hour after sub-plantar injection of brewers' yeast, the experimental compound, customarily dissolved in 1% TWEEN-80, is orally administered to rats usually at a standard dose-volume of 0.5 ml/100 g body weight. C- At 1, and 3 hours after administration of the test substance on the vehicle, the experimental or control nimals, respectively, are tested for determining their reaction threshold-to pressure: applied to the inflamed foot by employing the BASILE-Analgesy-Meter. This instrument is basically a device which exacts force that increases at a constant rate (a certain number of grams per second). The force of pressure required to produce the typical escape response, exhibited by the -animal as a noticeable struggle-to.- withdraw the inflamed foot -(sometimes accompanied by vocalization), is read off the instrument's scale and recorded. Note: In case weight discs are being used to increase the force of pressure applied, the same number of discs should be employed throughout the entire experiment for both experimental and control animals. For detailed operation of the analgesy-Jneter reference is trade to the specific instructions of the instrument given in the appendix. Calculation of Results a. The results of the recorded Pressure Reaction Thresholds (measured on the analgesy-meter scale calibrated in grams x 10) expressed as grams, are calculated as Mean Group Values + S.E.M. for each test group and testing period, i.e. 1, and 3 hours after test substance or vehicle administration. b. The differences in the various Mean Group Values between treatment and control groups are analyzed for statistical significance using the Student t-Test. Results: Table 3 EMI27.1 <tb> <SEP> % <SEP> of <SEP> % <SEP> of <SEP> % <SEP> effect <SEP> % <SEP> effect <tb> <SEP> Compound <SEP> control <SEP> control <SEP> vs. <SEP> parent <SEP> vs. <SEP> parent <tb> <SEP> 1 <SEP> hr <SEP> 3 <SEP> hrs <SEP> compound <SEP> compound <tb> <SEP> 1 <SEP> hr <SEP> 3 <SEP> brs <SEP> <tb> <SEP> Control <SEP> TWEEN <SEP> 100 <SEP> 100 <SEP> - <SEP> - <SEP> <tb> Indomethacin <SEP> 128 <SEP> 146 <SEP> - <SEP> Indomethacin-ECOE <SEP> ester <SEP> 130 <SEP> 153 <SEP> 102 <SEP> 105 <tb> <SEP> Aspirin <SEP> 126 <SEP> 100 <SEP> - <SEP> <tb> <SEP> Aspirin-ECOE <SEP> ester <SEP> 178 <SEP> 148 <SEP> 141 <SEP> 150 <tb> <SEP> Diclofenac <SEP> 123 <SEP> 133 <SEP> - <SEP> <SEP> Diclofenac-ECOE <SEP> ester <SEP> 106 <SEP> 110 <SEP> 86 <SEP> 82 <tb> <SEP> Ibuprofen <SEP> 152 <SEP> 145 <SEP> - <SEP> <SEP> Ibuprofen-ECOE <SEP> ester <SEP> 176 <SEP> 129 <SEP> '115 <SEP> 89 <tb> <SEP> Naproxen <SEP> 116 <SEP> 133 <SEP> - <SEP> - <SEP> <tb> <SEP> Naproxen-ECOE <SEP> ester <SEP> 125 <SEP> 121 <SEP> 108 <SEP> 91 <tb> 3. Ulcerogenicity. Methods: Six groups of 10 female Charles River rats weighing 170-230 g were used for each drug. Rats were fasted for a 24 hour period prior to experimentation, but were allowed free access to water during this period. Drugs were freshly suspended in water with 1% carboxy methyl cellulose and administered by stomach tube. Rats treated were sacrificed 5 hours after oral gavage. Ulcers were evaluated under a magnifying lens, after the stomach had been dissected out, opened along the lesser curvature and rinsed. Ulcer index (UI) for each group was calculated as the mean sum of the lengths of the individual lesions in each rat. Apparent maximal ulcerogenicity was calculatted from regression analysis of the ascending parts of each dose-response curve. Results: Table 4 EMI29.1 <tb> 5 <SEP> 4 <SEP> 3 <SEP> 2 <SEP> 1 <tb> Compound <SEP> Slope <SEP> UD50 <SEP> UI50 <SEP> UD <SEP> ma@ <SEP> UI <SEP> max <tb> <SEP> Uxkg/mmole <SEP> mm@le/kg <SEP> mmole/kg <tb> <SEP> Acetyl <tb> salicylic <SEP> acid <SEP> 33.7 <SEP> # <SEP> 11.5 <SEP> 0.02 <SEP> 46.3+ <SEP> 0.4 <SEP> 92.6 <tb> Acetyl <tb> salicylic <tb> acid-ECOE <SEP> ester <SEP> 13.7 <SEP> # <SEP> 6.5 <SEP> 0.02 <SEP> 20.5+ <SEP> 0.4 <SEP> 40.9 <tb> <SEP> Ibuprofen <SEP> 38.1 <SEP> # <SEP> 8.0 <SEP> 0.325 <SEP> 26.0 <SEP> 2.8 <SEP> 52.0 <tb> Ibuprofen ECOE <SEP> ester <SEP> 36.7 <SEP> # <SEP> 8.5 <SEP> 0.300 <SEP> 13.0 <SEP> 0.7 <SEP> 26.0 <tb> Indomethacin <SEP> 50 <SEP> - <SEP> - <SEP> 0.32 <SEP> 60 <tb> Indomethacin <tb> <SEP> ECOE <SEP> ester <SEP> 34 <SEP> # <SEP> <SEP> 13.8 <SEP> - <SEP> - <SEP> 0.32 <SEP> 42.0 <tb> Diclofenac <SEP> 31.1 <SEP> # <SEP> 8.7 <SEP> - <SEP> - <SEP> 0.6 <SEP> 61.8 <tb> Diclofenac ECOE <SEP> ester <SEP> 21.1 <SEP> - <SEP> - <SEP> 0.6 <SEP> 34.9 <tb> <SEP> Naproxen <SEP> 41.0 <SEP> # <SEP> 14.2 <SEP> 0.17 <SEP> 31.0+ <SEP> 2.0 <SEP> 62.0 <tb> <SEP> Naproxen <tb> <SEP> ECOE <SEP> ester <SEP> 63.5 <SEP> # <SEP> 0.59 <SEP> 0.59 <SEP> 32.5+ <SEP> 1.0 <SEP> 65.0 <tb> + doese response curve aquired bell shape - no plateau reached UI max - ulcerogenic index max UD max - dose causing max ulcerogenic index U150 - 50% of ulcerogenic index max UD50 - dose causing D1150 Bioavailability-phalmnBcokinetic profile in rats of ECOE ester of acetyl salicylic acid Methods: Female Charles River rats weighing 200-250 g were used. Rates were starved for a 24 hour period prior to each experiment, while water was allowed ad libitum. Aspirin or aspirin ECOE ester was freshly suspended in water with 1% carboxymethyl cellulose and administered by stomach tube at a dose of 0.4 mmole/kg. Blood was drawn from the tail at 0, 1/2, 1, 2 and 4 hours in one group, and at 0, 4, 6, 8, 12 and 24 hours in another group of rats. Plasma salicylate concentrations were measured by fluorometry according to Fret and El-Sayed (Arch. Int. Pharmacodyn. 230:300, 1977). The assay was found to be specific for salicylate and to exclude aspirin or aspirin derivative. Statistical evaluation was effected by (unpaired) Student t test. Results¯and Discussion: As figure 5 shows, plasma concentrations of salicylate rose quickly after aspirin had peaked at 121.3 7.9 g/ml after 1 hour, while the ascent after the derivative was more gradual, to reach a peak of 97.9 5.5 only after 4 hours. Thereafter, the salicylate concentrations did not differ significantly in the two groups. The areas under the plasma concentration-time curves were, however, not significantly different between the two groups neither at 0-4 hours (293.9 + 18.1 g/ml. hour for the derivative vs 373.3 + 52.9 for aspirin), nor at 4-24 hours (1440.6 + 67.D for the derivative vs 1553.3 i 161.2 for aspirin). From the above results one may conclude that aspirin ECOE ester acts as a prodrug and re]eases salicylate in rat plasma. Although the rate of appearance of salicylate seems slower after the oral gavage of the derivative than of plain aspirin, the bioavailability of salicylate from the derivative preparation seems complete. The slower build-up of salicylate levels may be related either to slower gastrointestinal absorption of the derivative or slower hydrolysis, or both. In view of the much smaller ulcerogenic liability of the derivative and considering its fair bioavailability as presently shown, aspirin ECOE ester seems to have significant advantages over Aspirin itself. Hydrolysis Ehe-rates of hydrolysis of acetyl salicylic acid ethoxy carbonyloxy ethyl ester to salicyl-ethoxy carbonyloxy ethyl ester in aqueous acidic system (simulated gastrointestinal juices) are given in the following table: Hydrolysis of Aspirin ester to Salicyl ester TIME tMin.) ESTER 0 100 30 96 60 92 90 90 120 90 150 180 82 210 76 Ethoxy carbonyloxy ethyl ester of Aspirin was dissolved to a prcdetermined concentration in an acidic aqueous medium (simulated gastric juice) mixture TIFF: aqueous conc. HC1 (1:1) and the rate of hydrolysis at 370C was measured by HPLC method. Salicyl 2-ethoxy carbonyloxy ethyl ester in the same experimental conditions was found to be stable. Stability of Salicyl - 2-Ethoxy carbonyloxy ethyl -ester TIwE (Min.) ESTER (%) 0 100 150 unchanged 180 210 240 11 The results of,all the above tests can be summarized as follows: The ethoxy carbonyloxy ethyl esters of non -steroidal anti-inflammatory drugs, the compounds of the present invention, have shown to possess a high degree of anti-inflammatory and analgesic activity with low toxicity, especially being less ulcerogenic than the parent acids, but retain their anti-infammatory activity The invention includes a pharmaceutical or veterinary formulation comprising an ester of the invention formulated for pharmaceutical or veterinary use, respectively, optionally together with an acceptable diluent, carrier or excipient and/or optionally in unit dosage form. The compounds of the present invention are conveniently administered to warm-blooded animals by conventional oral or topical aum3nstrat2.on. The ECOE esters of non-stero3dal anti-inflammatory substaxlces which are usually in the crystalline form, can be conveniently cambined with any suitable non-toxic pharmaceutically or veterinarily acceptable oral inert carrier materials to form tablets or capsules. Such carrier materials are well known to those skilled in the art of oral pharmaceutical or veterinary formulations. Those ECOE esters which are in a liquid form can be conveniently incorporated in softgelatine capsules as is well known to those skilled in the art, or be prepared in solution form. Similarly, any one of the compounds of the invention can be combined with a topical vehicle, such as triacetin, so that the active -ingredient is present in an effective amount. Such ;) preparation in the form of ointment@ @ream or @elly is applied topically to the inflammed area, whereby the therapeutically active compound is dermally absorbed and cleared to release the parent: moiety at the site of inflammation. The therapeutic dosage range for the compounds of the-invention will vary with the size and needs of the patient. However, generally the therapeutic oral dose of the compound of the present invention, mimics, on a molecular basis, the dose of the parent-conventional nonsteroidal anti-inflammatory moiety (e.g. aspirin, indomethacin, naproxen, etc.). For topical application, a 0.1t to 2.5e concentration of a compound of the present invention in a suitable topical carrier to the site of inflammation is sufficient. The compounds of the present invention are well absorbed percutaneously and consequently are by far more potent topically than the parent substance as they are poorly absorbed percutaneously. The compounds of the present invention are all lipid-soluble products. They are soluble in all conventional organic solvents including light petroleumether. Topical application of the said compounds has produced a higher anti-inflammatory potency than that of the parent compounds from which they, are derived. They penetrate easily through skin, and.hydrolyse enzymatically to release the parent non-steroidal anti-inflammatory agents at the target organ and bring' fast relief of rheumatic pains. The invention includes an ester of the invention for use as an anti-inflammatory prodrug.

Claims: CLAIMS: 1. An ester of the general formula EMI35.1 in which EMI35.2 is the acyl residue of a non-steroidal anti-inflammatory compound containing a carboxylic acid function. 2. Any one of the following esters:2-(acetyloxy)benzoic acid 1 '-ethoxycarbonyloxy ethyl ester; salicylic acid 2-ethoxy carbonyloxy ethyl ester; 1- (p-chlorobenzoyl) -5-methoxy-2-methylindole-3-acetic acid 1'-ethoxycarbonyloxy ethyl ester; (+)-6-methoxy-a-methyl2-naphthaleneacetic acid 1'-ethoxycarbonyloxy ethyl ester; a-methyl-4-(2-methylpropyl)benzene - acetic acid 1'ethoxy- carbonyloxy ethyl ester; 2-[(2,6-dichlorophenyl)amino]benzene-acetic acid 1'-ethoxycarbonyloxy ethyl ester; m benzoyihydratropic acid 1'-ethoxycarbonyloxy ethyl ester; 2-[(2,3-dimethylphenyl)amino]-benzoic acid 1'-ethoxycarbonyloxy ethyl ester; (Z)-5-fluoro-2-methyl-1-[(4-methylsul- finyl) -phenyl) methylene]-1H-indene-3-acetic acid 1'ethoxycarbonyloxy ethyl ester; 2[[3-(trifluoromethyl)- phenyl) -amino] benzoic acid 1 '-ethoxycarbonyloxy ethyl ester; or 1-methyl-5-(&alpha;-methylbenzoyl)-1H-pyrrole-2- acetic acid 1 '-ethoxycarbonyloxy ethyl ester. 3. A process for preparing an ester as claimed in claim 1 or claim 2, which comprises reacting an acid of the general formula EMI36.1 wherein R-C- has the same meaning as given in claim 1, or a 0 carboxylate salt of such an acid, with a compound of the formula EMI36.2 wherein X represents a halogen atom. 4. A process as claimed in claim 3, wherein the halogen-containing reactant is 1-chloroethyl ethyl carbonate or 1-bromoethyl ethyl carbonate. 5. A pharmaceutical or veterinary formulation comprising an ester as claimed in claim 7 or claim 2 formulated for pharmaceutical or veterinary use, respectively, optionally together with an acceptable diluent, carrier oraexcipient and/or optionally in unit dosage form. 6. A formulation as claimed in claim 5 and adapted for oral administration. 7. A formulation as claimed in claim -5 and adapted for topical application. 8. A method of producing a pharmaceutical or veterinary formulation as claimed in any one of claims 5 to 7, which comprises formulating an ester as defined in claim 1 or claim 2 for pharmaceutical or veterinary use, respectively, optionally together with an acceptable diluent, carrier or excipient. 9. An ester as claimed in claim 1 or claim 2 for use as an anti-inflammatory prodrug.

Inventors: AVNIR, DAVID, LADKANI, DAVID, WEINER, BEN ZION, YELLIN, HAIM
Applicants: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Application year: 1983
Main classification: C07C69
IPC codes: C07C317, C07C67, A61K31, C07C209, A61P29, C07C211, A61P25, C07D209, C07C229, C07C313, C07C69, C07D207, C07C68